EPAS1 and renal cell carcinoma: More recently, the HIF-2α inhibitor, MK-6482, was granted accelerated approval by the FDA to treat patients with VHL disease-associated RCC (with nonmetastatic RCC tumors less than 3 centimeters in size, not in need for immediate surgery).